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AMPA – alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
BDNF – brain derived neurotrophic factor 
CMS – chronic mild stress model 
CREB – cAMP response element-binding protein 
CSF – cerebrospinal fluid 
ERK – extracellular signaling regulated kinase 
FST – forced swim test  
GABA – gamma aminobutyric acid 
GluA1 – glutamate A1 subunit  
mTOR – mammalian target of rapamycin 
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NMDA – N-methyl-D-aspartate 
OF – open field test 
PET – positron emission tomography 
PFC – prefrontal cortex 
SSRI – selective serotonin reuptake inhibitor 
SNRI – serotonin and noradrenaline reuptake inhibitor 
TrkB – tropomyosin receptor kinase B 
WB – Western Blot 





In recent years, major depressive disorder has been studied from many pathophysiolog-
ical perspectives and has been concluded as a multifactorial disease with complex inter-
actions between multiple signaling systems. The serotoninergic and noradrenergic sys-
tems are implicated in the depression symptoms. In general, antidepressants are created 
to improve serotoninergic system; however, leading to changes in homeostasis mecha-
nisms. Well known fact that classical antidepressants work only partially and with a de-
layed onset has triggered the emergence of novel antidepressant agents with supposedly 
more precise mechanisms of action and less unwanted side effects. They increase sero-
tonin levels in raphe nucleus that can lead to activation of autoreceptors and consequent 
decrease of serotonin in frontal cortex. A lot of attention has gained serotonin 1A hetero-
receptor and its associated mechanisms. NLX101 is a novel serotonin 1A receptor biased 
agonist that exhibits antidepressant characteristics in animal models. It has shown a func-
tional selectivity for specific G-protein alpha subunits and downstream pathways. Here, 
we reveal that systemic single dose administration of NLX101 shows antidepressant-like 
activity in Forced Swim Test, stimulates glutamate and dopamine release in prefrontal 
cortex dialysate, and increases phosphorylated protein, m-TOR, Glu1A, expression in 
prefrontal cortex. Overall, NLX101 shows rapid, but not sustained antidepressant-like ac-
tion at low doses. 
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Major depressive disorder (further: depression) is a serious and debilitating mood 
disorder that can be recurrent and chronic, with specific diagnostic criteria; it requires at 
least five different symptoms lasting for two weeks and one of them has to be anhedonia 
or depressed mood (American Psychiatric Association, 2013). It can also be diagnosed 
by severity using different clinical assessment scales. The symptoms can be classified 
into somatic (as weight loss or gain) and non-somatic (as decreased concentration or 
suicidal ideation) (Tolentino and Schmidt, 2018). It is an important cause of years lived 
with disability and significant contributor to mortality due to suicide. According to the World 
Health Organization, worldwide, more than 300 million people suffer from this disease 
(World Health Organization, 2017). About 20% of the treated patients suffer from 
treatment resistant depression (Jaffe et al., 2019), meaning that at least two 
antidepressants of the same or different class have not been effective; and only around 
30% of the treatment resistant patients achieve remission (Al-harbi, 2012). 
Depression is a multifactorial disease with many proposed theories of pathogenesis. For 
example, gamma-aminobutyric acid (GABA)-ergic deficit, neuroinflammation, 
immunology (role of cytokines), altered monoaminergic transmission, thyroid and 
hypothalamus-pituitary axis alterations, glutamatergic hypofunction, and neurogenesis 
are some of those (Pham and Gardier, 2019). Since the last century 1950s, it has been 
postulated, that the lack of monoamines (disruption of serotonergic and noradrenergic 
systems) in the brain is a major cause of the disease (Pytka et al., 2016). Antidepressant 
treatments have been based on this theory so far. As Adell and Artigas have already 
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demonstrated, antidepressants preferentially increase the levels of serotonin (5-HT) in 
raphe nuclei (Adell and Artigas, 1991) and not in the cortex. This theory also does not 
explain the rapid elevation of 5-HT levels in the neuronal synapsis that contradicts the 
delayed onset of the antidepressant therapeutic effect or that the lowering of 5-HT in the 
synapsis trough tryptophane reduction does not induce depression in healthy study 
participants (Liu et al., 2017). Later, in 1970s other ideas emerged opposing the 
monoamine theory of the depression. It was proposed that somatodendritic autoreceptor 
desensitization could lead to increased 5-HT levels; however, 5HT1A receptor 
antagonists have not been effective as antidepressants in clinical trials (Liu et al., 2017). 
In the serotonergic system, from all the receptor subtypes, 5-HT1A receptor seems to 
play a major role (Kaufman et al., 2016) and has been the most studied one and is 
involved in the mechanism of action of classical antidepressants. It takes part in diverse 
central nervous system processes, including cognition, and areas where it can have 
opposing functions (Newman-Tancredi, 2011). It is found as a presynaptic autoreceptor 
on soma and dendrites of serotoninergic neurons in the dorsal and medial raphe nuclei. 
Postsynaptic heteroreceptors are found in the brain areas with serotonergic innervation - 
limbic system (hippocampus, amygdala, septum) and prefrontal cortex (PFC), mainly on 
pyramidal cells and GABAergic interneurons (Santana et al., 2004), basically, in the brain 
regions involved in mood and anxiety (Garcia-Garcia et al., 2014). Some of the 5HT1A 
receptors have been found in the rat glia as well (Whitaker-Azmitia et al., 1993). These 
receptors can signal through G-protein dependent and, presumably, G-protein 
independent ways. 5HT1A receptors are coupled to the inhibitory G protein (Gαi/o) and 
usually inhibit adenylyl cyclase, thus reducing cyclic adenosine monophosphate (cAMP) 
3 
 
and protein kinase A action (Drago et al., 2008). However, many other signaling pathways 
have been reported. In the raphe nuclei the autoreceptor activation causes 
hyperpolarization and Gαi3 protein coupling, reduction of firing rate, and, consequently, 
lowering of the extracellular serotonin levels in the projection areas (Garcia-Garcia et al., 
2014). Invernizzi et al. also have reported that overload of extracellular 5-HT in the raphe 
area leads to autoreceptor activation and decrease of 5-HT in the frontal cortex (Invernizzi 
et al., 1992). Postsynaptic 5HT1A receptors modulate region-specific activity depending 
on the released 5-HT, they are usually coupled to G0 and Gi3 (Newman-Tancredi et al., 
2009). They are increased by SSRIs (selective serotonin reuptake inhibitors), tricyclic 
antidepressants, and electroconvulsive therapy through indirect or direct pathways 
(Savitz et al., 2009). Therefore, 5HT1A dysfunction can be another possible mechanism 
involved in depression pathophysiology (Savitz et al., 2009). Autoreceptors create a 
“short feedback loop” that modulates neurotransmitter synthesis and release (Drago et 
al., 2008). These receptors are responsible for the delayed effectiveness of 
antidepressants (SSRIs and selective noradrenaline and serotonin reuptake inhibitors 
(SNRIs)), which may be solved by the desensitization of 5HT1A autoreceptors leading to 
the increase of the extracellular 5-HT levels (Dawson et al., 2000). The heteroreceptor 
activation on pyramidal neurons in PFC also causes hyperpolarization by activating Gαi3 
and G o proteins (Garcia-Garcia et al., 2014). These receptors can be a potential target 
for the treatment of neuropsychiatric diseases. 5HT1A receptors are strong modulators 
of the 5-HT system, since they have different anatomical localization and G-protein 
coupling populations (Garcia-Garcia et al., 2014). The effects of pharmaceutical targeting 
may vary depending on the brain area involved; due to this difference in the regional 
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expression and downstream signaling regulation (Garcia-Garcia et al., 2014) (Newman-
Tancredi 2011). Therefore, binding at pre- and postsynaptic sites should be studied and 
equilibrated to achieve the desired pharmacological effect with minimal adverse events. 
Due to the fact that current pharmacological treatment is not always effective and is rather 
generalized, novel antidepressant agents are emerging. Specifically, glutaminergic 
system has gained growing attention. Ketamine has shown rapid and sustained (up to 1 
week) antidepressant mechanism of action (Zarate et al., 2006). Recently, esketamine, 
N-methyl-D-aspartate (NMDA) receptor antagonist, in the form of nasal spray in 
conjunction with an oral antidepressant was approved by the USA Food and Drug 
Administration for the patients with treatment-resistant depression and depression with 
suicidal ideations under strict conditions of use and follow-up (SPARVATO ®, prescription 
information, 2020); however, this drug also has unwanted risks, such as abuse, and 
psychiatric side effects (Sullivan et al., 2009). 
Many preclinical studies with animal models have shown that 5HT1A auto- and 
heteroreceptors are involved in the pathophysiology of depression (Overstreet et al., 
2003) (Lesch and Mössner, 1999). The role of these receptors in depression patients also 
has been proven in various studies. Postmortem studies regarding suicidal behavior have 
shown that the levels of this receptor are altered in the brain (Mann et al., 1989), and in 
vivo PET imaging reports on 5HT1A receptor have shown that availability is reduced in 
the drug-naïve patients with depression and binding potential in raphe nuclei 
autoreceptors is higher in medication-free patients that causes less 5-HT release 
(Hirvonen et al., 2008) (Sullivan et al., 2009). In animal behavioral tests, activation of this 
receptor at presynaptic site leads to anxiolytic activity, and activation in postsynaptic site- 
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to antidepressant activity (Newman-Tancredi, 2011). Some attempts in the field to 
overcome the classical antidepressant challenge have been made, for example, a drug 
SB-649915-B works as 5-HT transport inhibitor and a 5HT1A/B autoreceptor antagonist 
increasing extracellular 5-HT in cortex of rats (Hughes et al., 2007). However, it has been 
concluded that 5HT1A receptor activation in cortex is necessary as well. Clinically tested 
partial 5HT1A agonists do not show the necessary efficacy and have multiple receptor 
sites (Newman-Tancredi et al., 2021). Further development has led to discovery of many 
5HT1A agonists that couple to these receptors without selectivity, but it has been 
postulated that unselective activation of these receptors may lead to suboptimal 
therapeutic effect or even hormonal and cognitive side effects (Depoortère et al. 2019). 
Based on the fact that different 5HT1A receptor subpopulations are coupled to different 
G-proteins and therefore activate different signaling pathways, a concept of “biased 
agonism” has been developed (Newman-Tancredi, 2011).  
A novel agent NLX101 (also known as, F15599) works as a biased agonist (Figure 1), 
meaning it has “functional selectivity.” It has high affinity and selectivity for the 5HT1A 
heteroreceptor (Newman-Tancredi et al., 2021). It preferentially activates postsynaptic 
cortical 5HT1A receptors on the GABAergic neurons and not other supopulations of 
5HT1A (LLado-Pelfort et al., 2010). The high selectivity of this agonist is based also on 
the theory that in vivo effects are inhibited by administration of a selective 5HT1A receptor 
antagonist (Newman-Tancredi et al., 2021). In vitro, NLX101 shows very high activity for 
phosphorylated extracellular signaling regulated kinase (p-ERK) signal transduction that 
is similar to other biased agonists as NLX112 or 8-OH-DPAT. However, the observed in 
vitro results may not translate to activity in vivo (animal experiments) or in neuronal cells, 
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where it could be different due to possible additional signaling differences (Newman-
Tancredi et al., 2021). Other neuronal circuits may also be involved in the signaling that 














Figure 1. Proposed mechanism of action of the biased agonists. G1/2- G proteins; E1/2 – coupled 
effectors 
 
GABAergic inhibitory interneurons in PFC act inhibitory on pyramidal neurons, thus 
restricting the release of glutamate. However, if the pyramidal neurons are disinhibited 
via different receptors, they can start firing again. We hypothesize that the novel agent 
mechanism of action is based on this principle. 
The proposed mechanism of action of NLX101 is similar to that of ketamine: the 
disinhibition of cortical glutamatergic pyramidal neurons via 5HT1A heteroreceptors 
(NMDA receptors in case of ketamine) that inhibit cortical GABAergic interneurons and 
GABA release, consequently increasing glutamate release (Newman-Tancredi et al., 
Agonist A Biased agonist B Biased agonist A 
Receptor Receptor Receptor 
G1 G2 
E1 E2 
G1 G2 G1 G2 
E2 E2 E1 E1 
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2021). Consequently, glutamate activates postsynaptic alpha-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) receptors and specific downstream pathways that 
involve stimulation of rapid (Akt and ERK activation) and long-term effects (brain derived 
neurotrophic factor: BDNF, regulation); also involving other signaling molecules, as 
mammalian target of rapamycin (mTOR) (Pham and Gardier, 2019) (Lladó-Pelfort et al., 
2010). It has been postulated that NLX101 has a preferential selection for ERK1/2 
phosphorylation (Newman-Tancredi, 2011). ERK phosphorylation is necessary for the 
activation of cascade and subsequent regulation of gene expression trough transcription 
factors as cAMP response element-binding protein (CREB), and its deficits and thus 
inactivity in PFC and hippocampus have been associated with pathophysiology of 
depression in post-mortem brain of suicide subjects (Dwivedi et al., 2001). 
Regarding G-proteins, NLX101 shows different potency for G-protein subtypes; it 
preferentially activates Gαi over Gαo (Newman-Tancredi 2011), mainly activating brain 
regions involved in mood and cognition. Biased agonists have different interactions with 
5HT1A receptor and activation of G-proteins, which leads to involvement of different 
signaling cascades in the brain neurons (Newman-Tancredi et al., 2021). This, in theory, 
may improve quickly the depressive symptoms of the patients and reduce unwanted side 
effects, since it involves particular brain regions. 
In the present study, we examined the NLX101 effect on 5HT1A receptors ex vivo, in vivo, 









▪ The novel agent NLX101 has a potential fast-acting antidepressant effect in the rat 
depression models. 
o NLX101 might exhibit antidepressant characteristics in behavioral tests as 
FST and OF after a single dose of systemic administration; 
▪ NLX101 might show changes of neurotransmitter release in neurochemical studies 
as microdialysis; 
▪ NLX101 might reveal phosphorylated and non-phosphorylated protein (as mTOR, 
CREB, GluA1, BDNF, ERK) expression changes in molecular studies as WB. 


















Male, 2-3 months old, albino Sprague- Dawley rats were used in this study (Birth date 
01/02/21). They were housed in controlled temperature, humidity, and light conditions 




Animals were injected intraperitoneally F15599, 3-chloro-4-fluorophenyl-(4-fluoro-4{[(5-
methyl-pyrimidin-2-ylmethyl)-amino]-methyl}-piperidin-1-yl)-methanone) tosylate salt, 
(NLX101) (generally supplied by Neurolixis Inc., San Diego, California, USA) 0.16 mg/kg 
or vehicle (saline) 30 min before the behavioral test, before the tissue excision for Western 
Blot, or after 3 h stabilization in microdialysis. 
All the procedures involving the use of rats and their care were carried out with the 
previous approval of the Animal Care Committee of the Universidad de Cantabria. All 
animal protocols were realized in accordance to Spanish legislation and the European 
Communities Council Directive on “Protection of Animals Used in Experimental and Other 




Behavioral Tests  
 
All the tests were performed between 10.00 am and 14.00 pm by experimenters blinded 
to the treatment. Rats were habituated for at least 30 min before testing. The animals 
were weighted (300-350 g) before the injection. We used forced swim test (FST) and 
open field test (OF) for the assessment of the behavior in rats. The data was extracted 
from program ANY-MAZE and analyzed in MS Excel. The experimental groups were 




The locomotor activity was assessed in the OF test. Animals were placed in 4 open field 
boxes indirectly illuminated. The floor was covered with with a changeable opaque plastic 
base. The behavior of thr animals was recorded on a video (ANY maze, Stoelting Europe, 
Dublin, Ireland). Between each session the field was cleaned with alcohol and feces 
removed.The time spent in the zones (central, periphery zone) was evaluated in a 
different study group. This test was used as a screening method to see if there is no 
significant difference between both study groups and FST would be credible.  
 




Rats were placed in cylindrical tanks with the water temperature of 24±1° C at a level of 
30 cm. Three plexyglas cylinders (46 cm height, 20 cm diameter) were prepared and 
feces counted between each session.  We conducted a pretest of 15 min swimming 24 h 
before the actual test. The FST was conducted 30 mins, 24 h, and 7 days after the 
injection. On the 1st testing day the animals were injected 0.16 mg/kg NLX101 
intraperitoneally 30 mins before the test. Right after the test animals were removed from 
the tank, dried, and put back in their cages. 
The animals were positioned in the pool for 5 mins and their behavior recorded on a video 
(ANY maze, Stoelting Europe, Dublin, Ireland). Afterwards, we measured the time spent 
during swimming, immobility, and climbing divided into 5 second periods. The 




Western blot  
 
Western Blot (WB) was conducted to analyze the protein expression and their 
phosphorylated (active) forms. The animals used in this test were others than the ones 
used in behavioral paradigms.  
The weight of the animals was 250-300 g. The control group received saline (N=6) and 
the treatment group (N=6) NLX101 0.16 mg/kg (kg x 5ml/1000) injection. Rats were 
injected with 5-10 min intervals to avoid distress.  
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The drug injection before sacrifice: 
Day 1 – 30 min 
Day 2 – 60 min  
After sacrificing the animal, the tissue was dissected on the ice. Regions of interest were 
right and left PFC and right and left hippocampus. Afterwards, the tissue was preserved 
frozen in -80°C. For further analysis in WB the PFC was used.  
Sample preparation 
PFCs were weighted and, to gain the cell lysate to extract proteins from adherent cells, 
samples were homogenized 1:15 with homogenization buffer (10 mM HEPES (pH 7.4), 
1.5 mM MgCl2, 100 mM KCl) and 1% protease/phosphatase inhibitor cocktail (Sigma). 
Lysis buffer was added. The solubilized proteins were collected in the supernatant after 
centrifugation (14000 RPM, 10 mins, 4°C), put in a fresh tube and placed on ice for the 
further steps. Samples were prepared in Laemmly buffer (Laemmli Sample Buffer, BIO-
RAD, USA) containing beta-mercaptoethanol 5% boiled 100°C for 5 mins for the 
denaturation of proteins. Aliquotation of proteins with loading buffer and storage of 
samples at -80°C for further analyzes was done. The protein amount was quantified using 
the Bradford DC Protein assay, according to manufacturer’s protocol (Bio-RAD, USA) We 
calculated the total protein with reactives (quantification with spectrophotometry, 
extraction of data in to the program Graphpad and exel, comparison with the pattern graph 




In total, 180 µl per sample were collected. We used the supernatants (15 µl per pocket) 
for the protein separation by Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) discontinuous with stacking gel (4 % acrylamide) and in 8.5-15 % 
separation gels, depending on the molecular weight of each protein, at 100-160V. The 
electrophoresis was stopped when we observed that molecular weight marker 
(PageRulerTM Plus Prestained Protein Ladder, 10-250 kDa, ThermoFisher Scientific, 
USA) reached the limit of the gel. Afterwards, we marked membranes with the number 
and letter stickers, then the proteins were transferred on nitrocellulose membranes 
(transfer sandwich) (BioRad, USA) in a wet system 90 mins at 90-100 V (variable 
amperage) covered with ice. We blocked the membranes for nonspecific fixation of 
antibodies for 60 mins at room temperature in TBS-T buffer (tris-buffered saline 
containing 0.1 % Tween 20) with 5% skimmed powdered milk or for phosphorylated 
proteins - 3% skimmed powdered milk with 200 µl NaV and 100 µl NaF per 100 ml of milk.  
Antibody detection 
We incubated the membranes in 4-5 ml sealed plastic pockets overnight at 4°C with the 
primary antibodies (Table 1) diluted in blocking buffer for the detection of proteins CREB, 
p-CREB, mTOR, p-mTOR, BDNF, GluA1, p-GluA1, ERK, and p-ERK. Afterwards the 
membranes were washed in TBS-T buffer 3 times 15 mins. 
Then we incubated membranes for 60 mins at room temperature in darkness with 
secondary antibodies at a dilution of 1/15000 (anti-rabbit green anti-mouse red) to 
afterwards detect the fluorescence. The membranes were washed in TBS-T once again 
3 times for 15 mins. 
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The signal was detected using Odyssey CLx imaging system (LI-COR, USA). We 
quantified band intensities using densitometric analysis with Image Studio software (LI-
COR, USA). The optical densities were standardized to tubulin and protein revels were 







BDNF 14 ABCAM 1/250 Rabbit 
p-GluA1 100 ABCAM 1/250 Rabbit 
GluA1 100 ABCAM 1/10000 Rabbit 
ERK 42-44 ABCAM 1/1000 Rabbit 
p-ERK 42-44 SIGMA 1/200 Mouse 
mTOR 289 CELL 
SIGNALING 
1/1000 Rabbit 
p-mTOR 289 CELL 
SIGNALING 
1/250 Rabbit 
CREB 40 CELL 
SIGNALING 
1/500 Mouse 
p-CREB 46 CELL 
SIGNALING 
1/500 Rabbit 







To measure the changes in the extracellular monoamine concentration in the right 
mPFC after the administration of NLX101, intracerebral in vivo microdialysis was 
performed in rats. The rat age was 1-2 moths and weight 200-220 g. Five rats were in the 
control group and 5 in the treatment group. Animals were transformed from their home 
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cages to the novel environment for microdialysis (transparent acrylic box with sawdust on 
the floor) for adaptation on the day of surgery.  
For the catheter implantation: 4 mm long catheters with semipermeable membranes were 
prepared in advance. The rats were anesthetized with phenobarbital sodium 
intraperitoneally 60mg/kg. After the sedative effect was achieved, animals head was 
positioned according to inter-auricular distance. Section in the skin was made with a 
bisturi, 4 holes were made to implant 1 catheter and 3 screws for stabilization (AP, DV, 
L), meninges were perforated for the implantation, probe put in the DV, checked with 
water, and cement put to seal the catheter. Cement was made from a mixture of resin 
(TAB 2000) in powder and liquid to polymerize. The coordinates of catheter implantation 
were calculated according to the Bregma point (AP +3.2, L – 0.6, DV -5.4) and referring 
to the stereotaxic atlas (Paxinos and Watson, 2005). All the catheters were functional 
after the implantation and controlled with saline solution.  
Awake and freely moving rats, 24 hours after the implantation of probe, during the 
daytime, underwent: 1) 3 h of stabilization with continuous perfusion of artificial CSF (1.5-
1.65 ul/min flow), 2) afterwards each 20 min the dialysate sample collection of 30 µl during 
2 h, in total, collecting 6 samples that were used for basal values before the treatment, 3) 
injection of the NLX101 molecule 0.16 mg/kg intraperitoneally, 4) every 20 min the sample 
collection, taking 6 samples in total. All the samples were collected in microtubes 
containing 5 µl of 10 mM perchloric acid and put into the liquid chromatography device 
(HPLS) overnight. Afterwards levels of dopamine, 5-HT, glutamate, and NA concentration 






The statistical analysis was performed using a program GraphPad Prism 5 (GraphPad 
software, Inc). Experimental groups were compared using unpaired Student’s t-test. The 
microdialysis results were analyzed by ANOVA of repeated measures with treatment and 
time as factors, with post hoc analysis (Tukey’s test). The results were expressed as 
mean of percentages with the respect to basal levels of neurotransmitters (100%) ±SEM.  
















Open Field Test 
 
 
Figure 2. Open field test revealed no significant difference between the vehicle and NLX101 
The test was used for the control/reliability of the FST, to analyze whether results of FST 
are associated with depression-like state and not with general animal activity. Six animals 
received NLX101 and six – vehicle. No significant difference was found in the results of 
locomotor activity. (p=0.1799), see Figure 1. 
 
 







Figure 3. Antidepressant-like effects in the Forced Swim Test. The results 30 mins, 24 h, and 7 
days after a single dose of intraperitoneal administration (0.16 mg/kg) revealed that NLX101 
decreased immobility and increased swimming compared with control group. *p<0.05 
 
During the FST no significant difference between control group and treatment group was 
found in swimming, climbing, and immobility 24h and 7 days after the treatment with 
NLX101. However, a significant difference was observed in swimming and immobility on 
the administration day (30 min before the test). The treatment group showed less 
immobility and more swimming compared with the control group. Students two-tailed t-
test for the results of FST 30 mins showed: Immobility t=3.186, df=8, p=0.0129; swimming 






No statistical significance was achieved for proteins BDNF (p=0.4177) and pCREB 
(p=0.1747) after 30 mins of the NLX101 injection. Non-phosphorylated forms of proteins 
did not reach any statistical significance level neither. However, we observed significant 
increase in levels of p-mTOR 30 mins after injection and p-Glu1A 60 mins after injection. 
BDNF results did not reach statistical significance at 30 mins or 60 mins (p =0.0522); 
however, 2 hours after injection an increase in BDNF level was observed, but this is out 
of the scope of this paper. Regarding protein ERK, its levels were increased 30 and 60 
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mins after injection, although, not reaching statistical significance. We can postulate that 
p-CREB and ERK (15-40 mins) levels raise to significant levels before 30 mins and, 

















First 4 values were obtained to find out basal levels of the neurotransmitters. Results 
revealed that after the administration of NLX101 during 20 min period increase of 
approximately 100% vs control was observed in the dopamineext and 50% vs control 
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glutamateext levels; however, no significant change (nor increase, nor decrease) was 
found in noradrenalineext and serotoninext levels. Results on glutamate by two-way 
ANOVA repeated measures indicated a significant effect of treatment: F(1,12)=7.351; 
p=0.018908, time: F(9,108)=4.311; p=0.000083, and interaction treatment x time: 
(9,108)=5.817; p=0,000001. Results on dopamine indicated a significant effect of 
treatment: F(1,11)= 7.1523; p=0.021624, but not  time: F(9,99)= 1.3555; p=0.218785 
(non-significant); and a significant effect of interaction treatment x time: (9,99)= 4.3049; 

















Figure 5. Release of the monoamine neurotransmitters in the mPFC after the systemic administration of 
NLX101 (0.16 mg/kg i/p). NLX101 stimulated the release of dopamineext and glutamateext in dialysate. The 
results are expressed as the mean of percentages +- SEM in respect to the basal levels. The arrow 
indicates the injection of NLX101. p<0.05; *p<0.0005. posy hoc Tukey’s test with ANOVA repeated 






We intended to find potential antidepressant characteristics of the novel agent NLX101 in 
rats in the current study. Newman-Tancredi has reported that in rats NLX101 exhibits 
potent antidepressant-like activity in the FST (Newman-Tancredi, 2011). It is widely 
accepted that FST is sensitive to activation of cortical 5HT1A heteroreceptors (Newman-
Tancredi et al., 2021). In our behavioral examinations FST results revealed decreased 
immobility and increased swimming time on the administration day (30 minutes). That 
could indicate the rapid effects of NLX101; however, short-term (24 hours after injection) 
and long-term (sustained effect of ketamine is 7 days) effects should be assessed and 
chronic stress models studied, to find out and conclude whether this molecule can have 
sustained effects. Also, chronic mild stress (CMS) model should be considered, since it 
has higher translational potential for mental disease studies, Depoortère et al. reported 
that in CMS NLX101 showed efficacy with a rapid antidepressant-like effect and that the 
effects were sustained during 2-week treatment and continued 4 weeks after stopping the 
therapy (Depoortère et al. 2019). 
Assie et al. have reported high antidepressant activity in acute and repeated 
administration of NLX101 to rats in FST by completely eliminating immobility. Moreover, 
they reported that NLX101 effects are continued with sustained reduction in immobility 
for at least 8 h (Assie et al. 2010). In our case, the immobility was significantly decreased 
only on the day of administration and no effect was seen 24 h or 7 days after the injection, 
we did not measure the effect 8 h after the administration. They also propose that CMS 
model should be used complementary to the FST. 
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In our microdialysis study NLX101 triggered the release of dopamine and glutamate in 
the rat PFC at the dose 0.16 mg/kg intraperitoneally. We did not study the dialysate of 
Raphe nuclei or ventral hippocampus (5-HT); therefore, it is not possible to comment 
directly on the autoreceptor involvement. However, no reduction in 5-HT levels was 
observed, which would indicate that the autoreceptors were not activated (Hjorth and 
Sharp, 1991), we can also assume from this that 5HT1A heteroreceptors on pyramidal 
neurons were not activated. Newman-Tancredi has reported that in microdialysis tests 
NLX101 modestly activates 5HT1A autoreceptors at higher dose than the one necessary 
to activate dopamine release in rat mPFC and that the chronically administered dose 
necessary to desensitize autoreceptors is very high (20 mg/kg for 14 days), which might 
give us an idea that this agonist has minimal effect on them (Newman-Tancredi, 2011). 
As Lladó-Pelfort and colleagues have already reported, NLX101 increases the dopamine 
levels in PFC, the effect that was significantly reversed by WAY100635, selective 5HT1A 
antagonist (Lladó-Pelfort et al., 2010). This is associated with 5HT1A heteroreceptor 
activation. Dopamine levels were elevated in our dialysate of the PFC. Most probably, 
NLX101 activated mesocortical dopaminergic neurons in the Ventral Tegmental Area via 
projections from pyramidal neurons in mPFC (Diaz-Mataix et al., 2005). Glutamate levels 
were significantly elevated plausibly trough disinhibition of GABAergic interneurons in the 
mPFC. Compared to a study with systemic administration of ketamine, where glutamate, 
noradrenaline, and 5-HT were elevated (Lopez-Gil et al., 2019), we found that 5-HT levels 
were not changed, which might give a clue that NLX101 has a short-term effect compared 
to ketamine. Our microdialysis data suggest that NLX101 preferentially activates 
postsynaptic 5HT1A heteroreceptors over presynaptic. 
23 
 
NLX101 at low doses stimulates rat medial PFC (mPFC) pyramidal neurons and 
dopamine release. It does not activate autoreceptors at low doses (Newman-Tancredi, 
2011). The 5HT1A biased agonist activity in different regions was proven by neuronal 
electric activity as well. The effects at auto- or heteroreceptor site can be distinguished 
by the firing rate of dorsal Raphe nucleus 5-HT neurons or of pyramidal neurons in cortex. 
NLX101 shows a dose-dependent inhibition of Raphe neuron firing and an increased 
firing of cortical pyramidal neurons at low doses, favorably activating pyramidal neurons 
(Llado-Pelfort et al., 2010). 
Newman-Tancredi and colleagues have reported that in ELISA analysis NLX101, 30 mins 
before sacrifice, shows modest inhibition of p-ERK in hippocampus and, at a same dose, 
significantly stimulates p-ERK in the frontal cortex, compared with other 5HT1A receptor 
biased agonists, as NLX112, that strongly inhibited p-ERK in the hippocampus at low 
dose, suggesting its preference for 5HT1A autoreceptors. The proposal that NLX101 
prefers to activate heteroreceptors is also based on the fact that it stimulates c-Fos 
expression in the frontal cortex rather than in raphe nucleus (Newman-Tancredi et al., 
2021). It has been postulated that NLX101 elevates ERK phosphorylation, compared with 
cAMP reduction, in the rat PFC, which is controlled by postsynaptic 5HT1A receptors and 
inhibits this pathway in hippocampus at similar doses (Newman-Tancredi et al., 2009). In 
our study, p-ERK levels elevated at 30 and 60 mins, but not significantly. Newman-
Tancredi has also proposed that the elevation in BDNF and ERK protein levels is 
responsible for the rapid action ox NLX101; however, we would like to propose that its 
rapid effects could be based on p-mTOR and p-GLUA1 increase in expression. Since 
BDNF involved in rapid processes can be the one from the reserves in vesicles (activity 
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dependent release) and not involving downstream pathways. In contrast, for the 
sustained antidepressant-like activity of ketamine, early activation of BDNF release and 
its binding to TrkB receptors in the hippocampus is necessary. (Pham and Gardier, 2019). 
We studied protein mTOR and its phosphorylated form. Our results revealed increased 
expression of p-mTOR. This is consistent with previous studies of ketamine mechanisms. 
Li and colleagues have reported that ketamine rapidly activates mTOR signaling pathway, 
which leads to increase in synaptic signaling proteins and, subsequently, increase in new 
spine synapses (Li et al., 2010). mTOR is phosphorylated trough activity-dependent fast 
release of BDNF and subsequent activation of TrkB and its downstream pathways PI3K-
Akt and MEK-ERK. Phospho-mTOR further increases local translation of the proteins as 
GluA1 (Duman et al., 2012).  
We also studied GluA1 and its phosphorylated form expression after administration of 
NLX101, since, to the best of our knowledge, no publications exist regarding this matter. 
GluA1 is one of the ionotropic glutamate receptor subunits that, together with other 
subunits, form a calcium-permeable AMPA receptor and trigger its integration into post-
synaptic membrane (Zhang and Abdullah, 2013). It has an important role in the synaptic 
plasticity. The increased expression and phosphorylation at serine831 or serine845 site of 
GluA1 subunit in the cortex and hippocampus is a known mechanism for the treatment of 
depression (Kiselycznyk et al., 2013). 
There were some limitations to this study. First, the number of animals could have been 
higher to gain statistical power. Second, there could be some bias in the analysis of FST, 
since it is a subjective evaluation based on the experience of evaluator. Third, since my 
work in the laboratory was one month long, some research was out of the scope of this 
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paper: we did not use other, higher doses of administration that might lead to activation 
of other receptor sites or lead to longer, more lasting effects; we could also study the 
effects of direct intracortical administration of NLX101 and compare them with system 
administration; we did not study the GABA release in dialysate. Forth, no correlation 
analyses were conducted, since we used different animals for behavioral and molecular 
tests; therefore, we can only conclude associations between the results. Currently, the 
work on this molecule is still in progress. It is therefore crucial to investigate in further 
studies the NLX101 preference to activate 5HT1A receptors on the GABAergic 
interneurons and not on the pyramidal neurons in the PFC, where this receptor has 





Single administration of NLX101 of 0.16 mg/kg systemically displayed rapid (30 min), but 
neither sustained (up to 24 h) neither long-term (up to 7 days), antidepressant-like effect 
in the forced swim test. Systemic (i/p) administration of NLX101 increases the efflux of 
dopamine and glutamate, but not noradrenaline nor serotonin in microdialysis study. 
Therefore, we can speculate that NLX101 works by previously mentioned theory of 
GABAergic interneuron disinhibition. NLX101 produced significant rise in p-mTOR protein 
expression 30 mins after the injection; in Glu1A protein expression 60 mins after injection. 
A rise in p-ERK levels was observed in WB of 30 and 60 mins; however, not reaching 
statistical significance, we assumed that its activation time is very short (less than 30 
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mins). Overall, NLX101 shows rapid, but not lasting synaptic actions at low doses. 
Possibly due to the activation of synaptic plasticity signaling pathways in the mPFC via p-
mTOR (activating mTORC1) and p-GluA1 (a major subunit of AMPA receptor) protein 
expression, and not preferentially via p-ERK and BDNF (since BDNF is activity-
dependent release) pathway as it has been presented in previous studies. Further 
investigation in rodents should be conducted, for example, with repeated dosing and in 
long-term or using chronic stress models. The NLX101 effects should be studied via 
translational methods between species to further develop it in the clinical setting for 
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